Factor H autoantibodies contribute to complement dysregulation in multisystem inflammatory syndrome in children (MIS‐C)

This publication has 10 references indexed in Scilit:

• TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C
  Journal of Experimental Medicine, 2021
• Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome
  Frontiers in Pediatrics, 2020
• Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)
  Pediatrics, 2020
• Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition
  Blood, 2020
• COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
  Laboratory Investigation, 2020
• Complement C5 inhibition in patients with COVID-19 - a promising target?
  Haematologica, 2020
• Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases
  Translational Research, 2020
• Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland
  Kidney International, 2017
• Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
  Kidney International, 2014
• Anti–factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome
  Blood, 2007